Limits...
Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP - J. Am. Coll. Cardiol. (2015)

Bottom Line: Patient groups were well matched for baseline clinical characteristics.Although there was no significant reduction in death or MI, a nonsignificant reduction in all primary endpoint components was seen.There was no reduction in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleeding, contrast-induced nephropathy, or stroke between the groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Sciences, University of Leicester and National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom. Electronic address: agershlick@aol.com.

No MeSH data available.


Related in: MedlinePlus

Patient Flow DiagramCONSORT (Consolidated Standards of Reporting Trials) diagram of recruitment to the CvLPRIT study. From 850 patients with ST-segment elevation myocardial infarction, 296 were randomized to receive complete (150) or culprit lesion–only (146) revascularization. Randomized patients were followed up for 12 months, and analysis was by intention-to-treat. CABG = coronary artery bypass grafting; CMR = cardiac magnetic resonance; IRA = infarct-related artery; ITT = intention-to-treat; MACE = major adverse cardiovascular event(s); MPS = myocardial perfusion scintigraphy; MVD = multivessel disease; N-IRA = non–infarct-related artery; PCI = percutaneous coronary intervention.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4359051&req=5

fig2: Patient Flow DiagramCONSORT (Consolidated Standards of Reporting Trials) diagram of recruitment to the CvLPRIT study. From 850 patients with ST-segment elevation myocardial infarction, 296 were randomized to receive complete (150) or culprit lesion–only (146) revascularization. Randomized patients were followed up for 12 months, and analysis was by intention-to-treat. CABG = coronary artery bypass grafting; CMR = cardiac magnetic resonance; IRA = infarct-related artery; ITT = intention-to-treat; MACE = major adverse cardiovascular event(s); MPS = myocardial perfusion scintigraphy; MVD = multivessel disease; N-IRA = non–infarct-related artery; PCI = percutaneous coronary intervention.

Mentions: We screened 850 patients for inclusion, and 296 were randomized (146 to IRA only and 150 to complete revascularization) (Figure 1). Patients in each treatment arm were well matched by demographic and baseline clinical characteristics, although there was a nonsignificant trend for more women in the IRA-only group. The proportion with 2- or 3-vessel disease, lesion locations, and N-IRA stenoses >70% were similar in each group (Table 1).


Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP - J. Am. Coll. Cardiol. (2015)

Patient Flow DiagramCONSORT (Consolidated Standards of Reporting Trials) diagram of recruitment to the CvLPRIT study. From 850 patients with ST-segment elevation myocardial infarction, 296 were randomized to receive complete (150) or culprit lesion–only (146) revascularization. Randomized patients were followed up for 12 months, and analysis was by intention-to-treat. CABG = coronary artery bypass grafting; CMR = cardiac magnetic resonance; IRA = infarct-related artery; ITT = intention-to-treat; MACE = major adverse cardiovascular event(s); MPS = myocardial perfusion scintigraphy; MVD = multivessel disease; N-IRA = non–infarct-related artery; PCI = percutaneous coronary intervention.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4359051&req=5

fig2: Patient Flow DiagramCONSORT (Consolidated Standards of Reporting Trials) diagram of recruitment to the CvLPRIT study. From 850 patients with ST-segment elevation myocardial infarction, 296 were randomized to receive complete (150) or culprit lesion–only (146) revascularization. Randomized patients were followed up for 12 months, and analysis was by intention-to-treat. CABG = coronary artery bypass grafting; CMR = cardiac magnetic resonance; IRA = infarct-related artery; ITT = intention-to-treat; MACE = major adverse cardiovascular event(s); MPS = myocardial perfusion scintigraphy; MVD = multivessel disease; N-IRA = non–infarct-related artery; PCI = percutaneous coronary intervention.
Mentions: We screened 850 patients for inclusion, and 296 were randomized (146 to IRA only and 150 to complete revascularization) (Figure 1). Patients in each treatment arm were well matched by demographic and baseline clinical characteristics, although there was a nonsignificant trend for more women in the IRA-only group. The proportion with 2- or 3-vessel disease, lesion locations, and N-IRA stenoses >70% were similar in each group (Table 1).

Bottom Line: Patient groups were well matched for baseline clinical characteristics.Although there was no significant reduction in death or MI, a nonsignificant reduction in all primary endpoint components was seen.There was no reduction in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleeding, contrast-induced nephropathy, or stroke between the groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Sciences, University of Leicester and National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom. Electronic address: agershlick@aol.com.

No MeSH data available.


Related in: MedlinePlus